Please assess the completion status of the following clinical trial:

Trial Title: S9624 Ifosfamide in Treating Patients With Meningeal Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven recurrent or unresectable:~* Malignant meningioma~* Intracranial hemangiopericytoma~* Primary central nervous system sarcoma, including:~* Fibrosarcoma~* Rhabdomyosarcoma~* Chondrosarcoma~* Leiomyosarcoma~* Measurable or evaluable disease on CT or MRI scan~* Persistent disease following biopsy or incomplete resection OR~* Recurrent disease following complete resection~* No benign meningioma~* No prior or current systemic sarcoma~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* SWOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No myocardial infarction within the past 3 months~* No active angina~* No unstable heart rhythms~* No congestive heart failure~Other:~* HIV negative~* No allergy to study drugs~* No serious concurrent medical or psychiatric illness~* No uncontrolled peptic ulcer disease~* No prior malignancy within past 5 years except adequately treated:~* Basal or squamous cell carcinoma of the skin~* Carcinoma in situ of the cervix~* Not pregnant or nursing~* Effective contraception required of fertile patients~PRIOR CONCURRENT THERAPY:~* Recovered from toxic effects of prior therapy and/or from postoperative complications~Biologic therapy:~* Not specified~Chemotherapy:~* No prior ifosfamide~* No other concurrent chemotherapy~Endocrine therapy:~* No concurrent hormonal therapy (except estrogen replacement therapy)~* Corticosteroids allowed if dose is stable or decreasing~Radiotherapy:~* At least 4 weeks since prior radiotherapy~* Progressive disease following radiation required~* No concurrent radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ifosfamide (Type: EXPERIMENTAL): ifosfamide

Based on this trial design, predict the completion outcome and termination type (if applicable).